Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q4 2016 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$12.39M$12.39Mderived+63.4% vs Q4 2015 Net Income$1.31M$1.31MderivedN/M vs Q4 2015 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$175,256−94.7% Operating Incomederived-$2,170,221N/M Operating Cash Flowderived$293,575−29.9% Margins · derivedGross margin1.4%−42.5 pt vs Q4 2015
Operating margin-17.5%−8.8 pt vs Q4 2015
Net margin10.6%+20.6 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 31, 2017 · 90 d after period end